Phenotypic and functional characterization of human bone marrow stromal cells in hollow-fibre bioreactors

Journal of Tissue Engineering and Regenerative Medicine

Volumn 6, Issue 5, 2012, Pages 369-377

  Li, Matthew ^a   Tilles, Arno W ^c   Milwid, Jack M ^a,b   Hammad, Mohamed ^a   Lee, Jungwoo ^a   Yarmush, Martin L ^a   Parekkadan, Biju ^a  

^a SHRINERS HOSPITALS FOR CHILDREN   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c Sentien Biotechnologies Inc   (United States)

Author keywords

Acute kidney failure; Dialysis; Mesenchymal stem cell

Indexed keywords

BIOCONVERSION; BIOREACTORS; BONE; DIALYSIS; FIBERS; FLOW OF FLUIDS; STEM CELLS;

ACUTE KIDNEY FAILURE; BONE MARROW STROMAL CELLS; CELL-BE; CELL/B.E; CELL/BE; HOLLOW FIBER BIOREACTOR; HUMAN BONE MARROW STROMAL CELLS; LARGE-SCALES; MESENCHYMAL STEM CELL; PHENOTYPIC CHARACTERIZATION;

CELL CULTURE;

POLYETHERSULPHONE; SULFONE; UNCLASSIFIED DRUG;

ARTICLE; BONE MARROW CELL; BONE MARROW STROMAL CELL; CELL CULTURE; CELL DIFFERENTIATION; FLUID FLOW; HOLLOW FIBER REACTOR; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; MEMBRANE; OSTEOBLAST; PHENOTYPE; PRIORITY JOURNAL; STROMA CELL;

EID: 84859959244     PISSN: 19326254     EISSN: 19327005     Source Type: Journal    
DOI: 10.1002/term.439     Document Type: Article

References (44)

1. Aguilar S, Nye E, Chan J, et al. 2007; Murine but not human mesenchymal stem cells generate osteosarcoma-like lesions in the lung. Stem Cells 25: 1586-1594.
2. Bianco P, Costantini M, Dearden LC, et al. 1988; Alkaline phosphatase positive precursors of adipocytes in the human bone marrow. Br J Haematol 68: 401-403.
3. Bianco P, Riminucci M, Kuznetsov S, et al. 1999; Multipotential cells in the bone marrow stroma: regulation in the context of organ physiology. Crit Rev Eukaryot Gene Expr 9: 159-173.
4. Carmeliet P, Ferreira V, Breier G, et al. 1996; Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380: 435-439.
5. Chen SL, Fang WW, Ye F, et al. 2004; Effect on left ventricular function of intracoronary transplantation of autologous bone marrow mesenchymal stem cell in patients with acute myocardial infarction. Am J Cardiol 94: 92-95.
6. Chung NG, Jeong DC, Park SJ, et al. 2004; Cotransplantation of marrow stromal cells may prevent lethal graft-versus-host disease in major histocompatibility complex mismatched murine hematopoietic stem cell transplantation. Int J Hematol 80: 370-376.
7. Ciccocioppo R, Bernardo ME, Sgarella A, et al. 2011; Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn's disease. Gut 60: 788-798.
8. Cressman DE, Greenbaum LE, DeAngelis RA, et al. 1996; Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice. Science 274: 1379-1383.
9. Gallucci RM, Simeonova PP, Matheson JM, et al. 2000; Impaired cutaneous wound healing in interleukin-6-deficient and immunosuppressed mice. FASEB J 14: 2525-2531.
10. Ge W, Jiang J, Arp J, et al. 2010; Regulatory T-cell generation and kidney allograft tolerance induced by mesenchymal stem cells associated with indoleamine 2, 3-dioxygenase expression. Transplantation 90: 1312-1320.
11. Gerlach JC. 2006; Bioreactors for extracorporeal liver support. Cell Transpl 15(suppl 1): S91-103.
12. Gnecchi M, He H, Liang OD, et al. 2005; Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells. Nat Med 11: 367-368.
13. Gnecchi M, He H, Noiseux N, et al. 2006; Evidence supporting paracrine hypothesis for Akt-modified mesenchymal stem cell-mediated cardiac protection and functional improvement. FASEB J 20: 661-669.
14. Gorter A, van de Griend RJ, van Eendenburg JD, et al. 1993; Production of bi-specific monoclonal antibodies in a hollow-fibre bioreactor. J Immunol Methods 161: 145-150.
15. Horwitz EM, Gordon PL, Koo WK, et al. 2002; Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: implications for cell therapy of bone. Proc Natl Acad Sci USA 99: 8932-8937.
16. Humes HD, MacKay SM, Funke AJ, et al. 1999; Tissue engineering of a bioartificial renal tubule assist device: in vitro transport and metabolic characteristics. Kidney Int 55: 2502-2514.
17. Jones E, McGonagle D. 2008; Human bone marrow mesenchymal stem cells in vivo. Rheumatology (Oxf) 47: 126-131.
18. Keller C, Steensberg A, Pilegaard H, et al. 2001; Transcriptional activation of the IL-6 gene in human contracting skeletal muscle: influence of muscle glycogen content. FASEB J 15: 2748-2750.
19. Kunter U, Rong S, Boor P, et al. 2007; Mesenchymal stem cells prevent progressive experimental renal failure but maldifferentiate into glomerular adipocytes. J Am Soc Nephrol 18: 1754.
20. Lamers CH, Gratama JW, Luider-Vrieling B, et al. 1999; Large-scale production of natural cytokines during activation and expansion of human T lymphocytes in hollow fiber bioreactor cultures. J Immunother 22: 299-307.
21. Lazarus HM, Haynesworth SE, Gerson SL, et al. 1995; Ex vivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal progenitor cells): implications for therapeutic use. Bone Marrow Transpl 16: 557-564.
22. Le Blanc K, Rasmusson I, Sundberg B, et al. 2004; Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 363: 1439-1441.
23. Lee RH, Pulin AA, Seo MJ, et al. 2009; Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell 5: 54-63.
24. Lin YC, Brayfield CA, Gerlach JC, et al. 2009; Peptide modification of polyethersulfone surfaces to improve adipose-derived stem cell adhesion. Acta Biomater 5: 1416-1424.
25. Maeda K, Mehta H, Drevets DA, et al. 2010; IL-6 increases B-cell IgG production in a feed-forward proinflammatory mechanism to skew hematopoiesis and elevate myeloid production. Blood 115: 4699-4706.
26. Maitra B, Szekely E, Gjini K, et al. 2004; Human mesenchymal stem cells support unrelated donor hematopoietic stem cells and suppress T-cell activation. Bone Marrow Transpl 33: 597-604.
27. Meinel L, Karageorgiou V, Fajardo R, et al. 2004; Bone tissue engineering using human mesenchymal stem cells: effects of scaffold material and medium flow. Ann Biomed Eng 32: 112-122.
28. Meisel R, Zibert A, Laryea M, et al. 2004; Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2, 3-dioxygenase-mediated tryptophan degradation. Blood 103: 4619-4621.
29. Nemeth K, Leelahavanichkul A, Yuen PS, et al. 2009; Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat Med 15: 42-49.
30. Ning H, Yang F, Jiang M, et al. 2008; The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: outcome of a pilot clinical study. Leukemia 22: 593-599.
31. Ortiz LA, Dutreil M, Fattman C, et al. 2007; Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury. Proc Natl Acad Sci USA 104: 11002-11007.
32. Parekkadan B, Milwid JM. 2010; Mesenchymal stem cells as therapeutics. Annu Rev Biomed Eng 12: 87-117.
33. Parekkadan B, van Poll D, Suganuma K, et al. 2007; Mesenchymal stem cell-derived molecules reverse fulminant hepatic failure. PLoS One 2: e941.
34. Pittenger MF, Mackay AM, Beck SC, et al. 1999; Multilineage potential of adult human mesenchymal stem cells. Science 284: 143-147.
35. Togel F, Zhang P, Hu Z, et al. 2009; VEGF is a mediator of the renoprotective effects of multipotent marrow stromal cells in acute kidney injury. J Cell Mol Med 13: 2109-2114.
36. Tumlin J, Wali R, Williams W, et al. 2008; Efficacy and safety of renal tubule cell therapy for acute renal failure. J Am Soc Nephrol 19: 1034-1040.
37. Unger RE, Huang Q, Peters K, et al. 2005; Growth of human cells on polyethersulfone (PES) hollow fiber membranes. Biomaterials 26: 1877-1884.
38. van Hall G, Steensberg A, Sacchetti M, et al. 2003; Interleukin-6 stimulates lipolysis and fat oxidation in humans. J Clin Endocrinol Metab 88: 3005-3010.
39. van Poll D, Parekkadan B, Cho CH, et al. 2008; Mesenchymal stem cell-derived molecules directly modulate hepatocellular death and regeneration in vitro and in vivo. Hepatology 47: 1634-1643.
40. Vianello F, Dazzi F. 2008; Mesenchymal stem cells for graft-versus-host disease: a double-edged sword? Leukemia 22: 463-465.
41. Yagi H, Parekkadan B, Suganuma K, et al. 2009; Long-term superior performance of a stem cell/hepatocyte device for the treatment of acute liver failure. Tissue Eng A 15: 3377-3388.
42. Yagi H, Soto-Gutierrez A, Navarro-Alvarez N, et al. 2010; Reactive bone marrow stromal cells attenuate systemic inflammation via sTNFR1. Mol Ther 18: 1857-1864.
43. Zangi L, Margalit R, Reich-Zeliger S, et al. 2009; Direct imaging of immune rejection and memory induction by allogeneic mesenchymal stromal cells. Stem Cells 27: 2865-2874.
44. Zhou X, Schmidtke P, Zepp F, et al. 2005; Boosting interleukin-10 production: therapeutic effects and mechanisms. Curr Drug Targets Immune Endocr Metabol Disord 5: 465-475.